TipRanks on MSN
IONS, IBTA, IRDM: Cathie Wood continues trimming stakes in Ionis, Ibotta, and Iridium stocks
Cathie Wood made a few trades across ARK ETFs on Friday, December 19, 2025, based on the daily trade filings. The filing ...
An Ionis Pharmaceuticals drug has preliminary data showing it met the main goal of its pivotal test in a rare disease with only a handful of approved treatments. With these results in hand, Ionis is ...
As it kicks off a pivotal phase 3 trial of its investigational treatment for Angelman syndrome (AS), Ionis Pharmaceuticals is ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Ionis on Tuesday said its new lipid-lowering drug ...
Zacks Investment Research on MSN
What awaits these 4 biotech stocks that more than doubled in 2025
After a weak first half, the drug and biotech sector regained momentum in the latter part of 2025, setting the stage for a ...
Ionis Pharmaceuticals has revenue from commercialized medicines, but those products reached the market in the hands of biopharma industry partners. The genetic medicines company does have wholly owned ...
Ionis Pharmaceuticals' Q4 earnings beat expectations, but guidance for 2025 was slightly below consensus, leading to a HOLD rating pending further catalysts. TRYNGOLZA's approval for FCS is promising, ...
CARLSBAD, Calif., Jan. 13, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2024 achievements and previewed important milestones expected ...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice ...
On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...
Carlsbad-based pharmaceutical company Ionis announced Wednesday that it has established a $25,000 scholarship to provide remote classes and therapy for San Diego-area ALS patients amid social ...
Here's what it takes to justify the current valuation. Corinne Cardina: Let's start with Ionis Pharmaceuticals. This was actually asked at 2:01, so props to this person who is really excited about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback